Transaction DateRecipientSharesTypePriceValue
23rd February 2021Neil Gagnon8,055Open or private purchase$4.62$37,181.88
23rd February 2021Neil Gagnon4,166Open or private purchase$4.62$19,230.26
22nd February 2021Neil Gagnon10,103Open or private purchase$4.80$48,523.70
18th February 2021Neil Gagnon378Open or private purchase$4.75$1,794.90
18th February 2021Neil Gagnon1,649Open or private purchase$4.75$7,830.11
5th February 2021Neil Gagnon15,488Open or private purchase$5.14$79,630.00
5th February 2021Neil Gagnon7,101Open or private purchase$4.84$34,343.99
5th February 2021Neil Gagnon30,954Open or private purchase$4.71$145,861.44
2nd February 2021Neil Gagnon10,873Open or private purchase$4.42$48,057.57
1st February 2021Neil Gagnon473Open or private purchase$4.20$1,988.02
Apollo Endosurgery
Apollo Endosurgery logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Apollo Endosurgery, Inc. engages in the design, development, and commercialization of medical devices. It offers medical devices for bariatric and gastrointestinal procedures under the ORBERA and OverStitch brands.


Ticker: APEN
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1251769
Employees: 217
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $19 M (-36%)
Inventory, Net: $11 M (0%)
Assets, Current: $39 M (-23%)
Other Assets, Noncurrent: $3 M (3%)
Assets: $60 M (-19%)
Long-term Debt, Current Maturities: $5 M (0%)
Accounts Payable, Current: $7 M (-27%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $19 M (-63%)
Liabilities: $71 M (-2%)
Common Stock, Value, Issued: $21 Th (0%)
Common Stock, Shares, Issued: $21 M (1%)
Retained Earnings (Accumulated Deficit): $267 M (6%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 M (147%)
Stockholders' Equity (Parent): $11 M (0%)
Liabilities and Equity: $60 M (-19%)
Revenue: $6 M (0%)
Cost of Revenue: $3 M (-61%)
Gross Margin: $2 M (-69%)
Research and Development: $2 M (-54%)
Sales and Marketing: $2 M (-73%)
General and Administrative Expenses: $2 M (-60%)
Operating Income/Loss: $4 M (-60%)
Income before taxes: $6 M (-62%)
Provision for income taxes: $6 Th (-87%)